Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin sBLA For Metastatic Breast Cancer Gets Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech reports that FDA has accepted its resubmitted application, which will be reviewed by the Oncologic Drugs Advisory Committee in December.

You may also be interested in...



FDA’s Oncologic Drugs Advisory Cmte. Will Review Avastin In Breast Cancer Dec. 5

ODAC will address Genentech’s sBLA for bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for locally recurrent or metastatic HER2 negative breast cancer.

FDA’s Oncologic Drugs Advisory Cmte. Will Review Avastin In Breast Cancer Dec. 5

ODAC will address Genentech’s sBLA for bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for locally recurrent or metastatic HER2 negative breast cancer.

Genentech Product Sales Rise 18 Percent, Led By Avastin, Though Lucentis A Disappointment

Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .

Related Content

Topics

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel